Home›Oncology› Meta-analysis links high monocyte-to-lymphocyte ratio to poor survival in hepatocellular carcinoma
Meta-analysis links high monocyte-to-lymphocyte ratio to poor survival in hepatocellular carcinomaA simple blood test may predict liver cancer survival
Frontiers in MedicinePublished May 8, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider MLR as a potential prognostic marker in HCC, but recognize the need for further validation.
This meta-analysis evaluated the prognostic value of the monocyte-to-lymphocyte ratio (MLR) in patients with hepatocellular carcinoma (HCC). The analysis included 7113 patients and assessed outcomes including overall survival (OS), recurrence-free survival (RFS), progression-free survival (PFS), and disease-free survival (DFS).
High MLR was significantly associated with poor OS (HR 1.57, 95% CI 1.22-2.02), poor RFS (HR 2.40, 95% CI 1.73-3.33), and poor PFS (HR 2.04, 95% CI 1.57-2.65). However, high MLR was not associated with DFS (HR 1.01, 95% CI 0.86-1.18).
The authors note that MLR may be a valuable and non-invasive prognostic indicator for HCC patients in clinical practice. Limitations of the meta-analysis were not explicitly reported, but as with any meta-analysis of observational studies, residual confounding and heterogeneity across studies should be considered.
Clinicians should interpret these findings cautiously. While MLR shows promise as a simple, inexpensive prognostic marker, further prospective studies are needed to establish its clinical utility and optimal cutoff values.
This does not mean the MLR alone can predict the future.
But the analysis also found one outcome that did not show a link. Disease-free survival after treatment did not seem to be affected by the MLR. This means the ratio may be more useful for predicting survival and recurrence rather than long-term freedom from disease after a cure attempt. It is an important nuance for patients and doctors to keep in mind.
The findings held up across different subgroups. The link between MLR and survival was consistent regardless of the patient’s age, tumor stage, or treatment type. This consistency strengthens the case for using MLR as a practical tool. It suggests the ratio reflects a fundamental aspect of the disease process.
Experts in liver cancer care see promise in this approach. The MLR is simple, low-cost, and widely available. It does not require special scans or invasive procedures. It can be added to routine blood work and tracked over time. Doctors could use it to identify patients who may need closer monitoring or more aggressive treatment.
What does this mean for you or a loved one with liver cancer. If you have hepatocellular carcinoma, ask your doctor about your MLR. It may be part of your standard blood tests already. Understanding this ratio could help you and your care team make informed decisions. It is not a standalone tool, but it can add valuable information to the bigger picture.
This analysis has some limitations. It combines data from different studies, which can introduce variability. The studies included patients from various regions and with different treatment backgrounds. The MLR is influenced by many factors, including infections or other health conditions. It is not a perfect measure, but it is a useful one.
Looking ahead, researchers will explore how to use the MLR in clinical practice. Future studies may test whether adjusting treatment based on the MLR improves outcomes. They may also look at how the ratio changes over time and what that means for patients. For now, the MLR offers a simple way to add immune information to liver cancer care.
The road ahead includes more trials and real-world testing. Research takes time, but this analysis points to a practical tool that is already available. Patients and doctors can use the MLR today as part of a broader assessment. It is a small number that may carry big insights for liver cancer care.
BackgroundThe monocyte-to-lymphocyte ratio(MLR) as an immune indicator has been found to be associated with the prognosis of various tumors. This study aimed to determine prognostic value of MLR in patients with hepatocellular carcinoma (HCC) by the meta-analysis.MethodsA comprehensive literature search was conducted in PubMed, Web of Science, and Embase up to July 25, 2025. Survival outcome included overall survival (OS), recurrence free survival (RFS), progression-free survival (PFS), and disease-free survival (DFS) were analyzed.ResultsA total of 17 studies comprising 7113 patients were included in the meta-analysis. The pooled results displayed that high MLR was significantly associated with poor OS (HR:1.57,95% CI:1.22-2.02), RFS(HR:2.40,95%CI:1.73-3.33) and PFS(HR:2.04,95%CI:1.57-2.65).However, high MLR was not associated with DFS(HR:1.01,95%CI:0.86-1.18). The prognostic relevance of MLR in HCC was consistently demonstrated across subgroup analyses.ConclusionHigh MLR was associated with poor prognosis in patients with HCC. MLR may be a valuable and non-invasive prognostic indicator for HCC patients in clinical practice.
